Hepion Pharmaceuticals acquires Gravitas Life Sciences in cash-and-stock deal
HEPA•Hepion Pharmaceuticals acquired all outstanding membership interests in Gravitas Life Sciences on Oct. 6, 2026, for $2 million and 25 million common shares, subject to a 19.99% issuance cap, with any shortfall settled in cash.
1. Deal terms
Hepion also paid the seller $135,000 at closing. It paid $1 million to Canton Strategic Holdings, while Gravitas made a $125,000 mandatory prepayment on a promissory note. Hepion assumed the remaining Canton note obligations and became the sole maker, obligor and guarantor.
